

# CITATION REPORT

List of articles citing

Medication-assisted treatment of opioid use disorder:  
review of the evidence and future directions

DOI: 10.1097/hrp.00000000000000075

Harvard Review of Psychiatry, 2015, 23, 63-75.

**Source:** <https://exaly.com/paper-pdf/62354774/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
385	Caring for pregnant opioid abusers in Vermont: A potential model for non-urban areas. <b>2015</b> , 80, 18-22		13
384	Police, Law Enforcement and HIV. <b>2016</b> , 19, 21260		
383	Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy. <b>2016</b> , 19, 20897		29
382	Optimising health and safety of people who inject drugs during transition from acute to outpatient care: narrative review with clinical checklist. <b>2016</b> , 92, 356-63		18
381	Outcomes for Physicians With Opioid Dependence Treated Without Agonist Pharmacotherapy in Physician Health Programs. <i>Journal of Substance Abuse Treatment</i> , <b>2016</b> , 64, 47-54	4.2	59
380	Predictors of early dropout in outpatient buprenorphine/naloxone treatment. <b>2016</b> , 25, 472-7		45
379	Bibliography: Schizophrenia: Advances in Understanding and Treatment. <b>2016</b> , 14, 361-362		
378	Substance Use Disorders and Schizophrenia. <b>2016</b> , 14, 333-342		2
377	Stressful Events and Other Predictors of Remission from Drug Dependence in the United States: Longitudinal Results from a National Survey. <i>Journal of Substance Abuse Treatment</i> , <b>2016</b> , 71, 41-47	4.2	22
376	An urgent call to increase access to evidence-based opioid agonist therapy for prescription opioid use disorders. <b>2016</b> , 188, 1208-1209		14
375	Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. <i>Addiction</i> , <b>2016</b> , 111, 695-705	4.6	126
374	Linkage to Primary Care for Persons First Receiving Injectable Naltrexone During Inpatient Opioid Detoxification. <i>Journal of Substance Abuse Treatment</i> , <b>2016</b> , 64, 44-6	4.2	8
373	Urine drug testing results and paired oral fluid comparison from patients enrolled in long-term medication-assisted treatment in Tennessee. <i>Journal of Substance Abuse Treatment</i> , <b>2017</b> , 76, 36-42	4.2	13
372	The association of psychiatric comorbidity with treatment completion among clients admitted to substance use treatment programs in a U.S. national sample. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 175, 157-163	4.9	57
371	The Opioid Epidemic: Searching for Answers. <b>2017</b> , 31, 141		
370	Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multistate Population. <b>2017</b> , 55, 669-676		49
369	Heroin refusal self-efficacy and preference for medication-assisted treatment after inpatient detoxification. <b>2017</b> , 73, 124-128		4

368	Buprenorphine implants in medical treatment of opioid addiction. <b>2017</b> , 10, 799-807		3
367	Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women. <b>2017</b> , 37, 824-839		35
366	Social-demographic shift in drug users at the first-ever- methadone maintenance treatment in Wuhan, China. <b>2017</b> , 7, 11446		5
365	Opioid tapering in patients with prescription opioid use disorder: A retrospective study. <b>2017</b> , 17, 167-173		3
364	Deaths from Opioid Overdosing: Implications of Coroners' Inquest Reports 2008-2012 and Annual Rise in Opioid Prescription Rates: A Population-Based Cohort Study. <b>2017</b> , 6, 203-215		26
363	Overcoming Barriers to Initiating Medication-assisted Treatment for Heroin Use Disorder in a General Medical Hospital: A Case Report and Narrative Literature Review. <b>2017</b> , 23, 221-229		17
362	Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample. <i>Drug and Alcohol Dependence</i> , <b>2017</b> , 178, 512-518	4.9	57
361	Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods. <b>2017</b> , 60, 105-112		18
360	Only One In Twenty Justice-Referred Adults In Specialty Treatment For Opioid Use Receive Methadone Or Buprenorphine. <b>2017</b> , 36, 2046-2053		81
359	Endocrinological Effects of Drugs of Abuse. <b>2017</b> , 403-420		
358	Buprenorphine Treatment for Adolescents and Young Adults With Opioid Use Disorders: A Narrative Review. <i>Journal of Addiction Medicine</i> , <b>2018</b> , 12, 170-183	3.8	28
357	Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. <i>Addiction</i> , <b>2018</b> , 113, 1477-1487	4.6	17
356	Coverage of Medications That Treat Opioid Use Disorder and Opioids for Pain Management in Marketplace Plans, 2017. <b>2018</b> , 56, 505-509		14
355	A Review of the Opioid Epidemic: What Do We Do About It?. <b>2018</b> , 7, 23-36		69
354	A novel approach to treating adolescents with opioid use disorder in pediatric primary care. <b>2018</b> , 39, 173-181		13
353	ENDING THE OPIOID EPIDEMIC REQUIRES A HISTORIC INVESTMENT IN MEDICATION-ASSISTED TREATMENT. <b>2018</b> , 37, 431-438		12
352	Trends in AIDS Mortality, Retention in Opioid Agonist Therapy, and HIV RNA Suppression in HIV-Infected People Who Injected Drugs from 2000 to 2015. <b>2018</b> , 22, 2766-2772		1
351	Extended-release injectable naltrexone for opioid use disorder: a systematic review. <i>Addiction</i> , <b>2018</b> , 113, 1188-1209	4.6	106

350	Treatment Persistence Among Insured Patients Newly Starting Buprenorphine/Naloxone for Opioid Use Disorder. <b>2018</b> , 52, 405-414		16
349	Stigma at every turn: Health services experiences among people who inject drugs. <i>International Journal of Drug Policy</i> , <b>2018</b> , 57, 104-110	5.5	173
348	Concomitant use of buprenorphine for medication-assisted treatment of opioid use disorder and benzodiazepines: Using the prescription behavior surveillance system. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 187, 221-226	4.9	12
347	Tackling an Epidemic: New and Emerging Opioid Addiction Treatments Offer Hope for Solutions to This Crisis. <b>2018</b> , 9, 22-25		2
346	Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults. <i>Journal of Substance Abuse Treatment</i> , <b>2018</b> , 85, 38-44	4.2	10
345	Addressing Host Factors: Primary, Secondary, and Tertiary Prevention of Opioid Dependence. <b>2018</b> , 265-290		0
344	Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis. <b>2018</b> , 87, 126-146		59
343	Patterns of buprenorphine use and risk for re-arrest among highly vulnerable opioid-involved women released from jails in rural Appalachia. <b>2018</b> , 37, 1-4		8
342	Double jeopardy: a review of weight gain and weight management strategies for psychotropic medication prescribing during methadone maintenance treatment. <b>2018</b> , 30, 147-154		7
341	Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016. <b>2018</b> , 1, e186371		101
340	Evaluating Slow-Release Oral Morphine to Narrow the Treatment Gap for Opioid Use Disorders. <b>2018</b> , 168, 141-142		12
339	Methadone Maintenance Treatment Reduces the Vulnerability of Drug Users on HIV/AIDS in Vietnamese Remote Settings: Assessing the Changes in HIV Knowledge, Perceived Risk, and Testing Uptake after a 12-Month Follow-Up. <i>International Journal of Environmental Research and Public Health</i> , <b>2018</b> , 15,	4.6	4
338	Expanding access to buprenorphine treatment in rural areas with the use of telemedicine. <b>2018</b> , 27, 612-617		50
337	Commentary: Applying the Community Partners in Care Approach to the Opioid Crisis. <b>2018</b> , 28, 381-388		3
336	Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys. <b>2018</b> , 840, 28-32		18
335	Utilization of the Nurse Practitioner Role to Combat the Opioid Crisis. <b>2018</b> , 14, e213-e216		4
334	Physician Autonomy and the Opioid Crisis. <b>2018</b> , 46, 203-219		8
333	Emerging Evidence for Cannabis' Role in Opioid Use Disorder. <b>2018</b> , 3, 179-189		68

332	Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management. <i>Journal of Substance Abuse Treatment</i> , <b>2018</b> , 94, 55-59	4.2	21
331	Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. <i>Addiction</i> , <b>2018</b> , 113, 1840-1849	4.6	16
330	Federal Response to the Opioid Crisis. <b>2018</b> , 15, 293-301		27
329	The role of health insurance on treatment for opioid use disorders: Evidence from the Affordable Care Act Medicaid expansion. <b>2018</b> , 60, 177-197		94
328	State Responses to the Opioid Crisis. <b>2018</b> , 46, 367-381		27
327	Opioid Use Disorders in Adolescents-Updates in Assessment and Management. <b>2018</b> , 6, 99-106		11
326	Treatment Approaches for Opioid Use Disorders in Late Life. <b>2018</b> , 5, 242-254		
325	Opioid-related mortality in rural America: Geographic heterogeneity and intervention strategies. <i>International Journal of Drug Policy</i> , <b>2018</b> , 57, 119-129	5.5	130
324	Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives. <b>2018</b> , 86, 111-117		36
323	Impact Of Medicaid Expansion On Coverage And Treatment Of Low-Income Adults With Substance Use Disorders. <b>2018</b> , 37, 1208-1215		38
322	Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?. <b>2018</b> , 15, 266-275		34
321	Opioid Misuse as a Predictor of Alcohol Treatment Outcomes in the COMBINE Study: Mediation by Medication Adherence. <b>2018</b> , 42, 1249-1259		9
320	Physician prescribing of opioid agonist treatments in provincial correctional facilities in Ontario, Canada: A survey. <b>2018</b> , 13, e0192431		13
319	Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016. <i>Drug and Alcohol Dependence</i> , <b>2018</b> , 189, 90-95	4.9	38
318	Interest in Getting Help to Reduce or Stop Substance Use Among Syringe Exchange Clients Who Use Opioids. <i>Journal of Addiction Medicine</i> , <b>2018</b> , 12, 428-434	3.8	21
317	Taking Stock of Drug Courts: Do They Work?. <b>2019</b> , 14, 283-298		15
316	Unmet mental health and substance use treatment needs among older homeless adults: Results from the HOPE HOME Study. <b>2019</b> , 47, 1893-1908		8
315	Legal and policy changes urgently needed to increase access to opioid agonist therapy in the United States. <i>International Journal of Drug Policy</i> , <b>2019</b> , 73, 42-48	5.5	20

314	Perceptions about fentanyl-adulterated heroin and overdose risk reduction behaviors among persons seeking treatment for heroin use. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 104, 144-147	4.2	9
313	Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?. <i>Addiction</i> , <b>2019</b> , 114, 1992-1999	4.6	16
312	Opioid maintenance, weaning and detoxification techniques; where we have been, where we are now and what the future holds: an update. <b>2019</b> , 9, 297-306		
311	Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events?. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 105, 37-43	4.2	11
310	A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 104, 135-143	4.2	10
309	Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment. <b>2019</b> , 9, e026604		8
308	Translating Neurobiology into Practice in Tobacco, Alcohol, Drug, and Behavioral Addictions. <b>2019</b> , 29, 389-401		
307	Novel Formulations of Buprenorphine for Treatment of Opioid Use Disorder. <b>2019</b> , 17, 104-109		3
306	Hospital Opioid Requirements Following Continuation Versus Discontinuation of Buprenorphine for Addiction - A Retrospective Cohort Study. <b>2019</b> , 33, 98-106		
305	Dissociable neural substrates of opioid and cocaine use identified via connectome-based modelling. <b>2021</b> , 26, 4383-4393		12
304	Adjunctive memantine for opioid use disorder treatment: A systematic review. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 107, 38-43	4.2	5
303	Treatment of Opioid Use Disorder in Pediatric Medical Settings. <b>2019</b> , 6, 374-382		3
302	U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018. <i>Drug and Alcohol Dependence</i> , <b>2019</b> , 204, 107527	4.9	30
301	Association of Methadone Treatment With Substance-Related Hospital Admissions Among a Population in Canada With a History of Criminal Convictions. <b>2019</b> , 2, e190595		4
300	Multi-model implementation of evidence-based care in the treatment of opioid use disorder in Pennsylvania. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 106, 58-64	4.2	25
299	Current understanding of the neurobiology of opioid use disorder: An overview. <b>2019</b> , 6, 1-11		5
298	Emergency Department Visits and Overnight Hospital Stays among Persons Aged 50 and Older Who Use and Misuse Opioids. <b>2019</b> , 51, 37-47		1
297	Comparison of opioid use disorder among male veterans and non-veterans: Disorder rates, socio-demographics, co-morbidities, and quality of life. <b>2019</b> , 28, 92-100		26

296	Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 103, 1-8	4.2	46
295	Problematic use of prescription opioid drugs: Classification and effective treatments. <b>2019</b> , 152, 458-465		
294	Emergency Department Risk Stratification After Opiate Overdose Is Just the Beginning. <i>Academic Emergency Medicine</i> , <b>2019</b> , 26, 944-945	3.4	
293	Buprenorphine Treatment for Opioid Use Disorder: An Overview. <b>2019</b> , 33, 567-580		27
292	The case for a medication first approach to the treatment of opioid use disorder. <b>2019</b> , 45, 333-340		17
291	A Retrospective 4-year Outcome Study of Veterans Admitted to an Acute Inpatient Detoxification Unit for Opioid Use Disorder. <b>2019</b> , 28, 318-323		13
290	Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. <i>Harm Reduction Journal</i> , <b>2019</b> , 16, 31	4.6	12
289	Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder. <i>Addiction</i> , <b>2019</b> , 114, 1416-1426	4.6	45
288	Research and policy priorities for addressing prenatal exposure to opioids in Alaska. <b>2019</b> , 78, 1599-275		1
287	The opioid crisis: Origins, trends, policies, and the roles of pharmacists. <b>2019</b> , 76, 424-435		29
286	Adults who misuse opioids: Substance abuse treatment use and perceived treatment need. <b>2019</b> , 40, 247-255		6
285	Successful treatment with slow-release oral morphine following afentanyl-related overdose: A case report. <b>2019</b> , 40, 473-475		2
284	Discharge against medical advice from hospitalizations for substance use disorders: The potential impact of the Affordable Care Act. <i>Drug and Alcohol Dependence</i> , <b>2019</b> , 197, 115-119	4.9	6
283	Problematic use of prescription opioid drugs: Classification and effective treatments. <b>2019</b> , 152, 458-465		3
282	Challenges on the road to recovery: Exploring attitudes and experiences of clients in a community-based buprenorphine program in Baltimore City. <b>2019</b> , 93, 14-19		10
281	Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study. <b>2019</b> , 171, 1-9		45
280	Predictors of Medication-Assisted Treatment Initiation for Opioid Use Disorder in an Interdisciplinary Primary Care Model. <b>2019</b> , 32, 724-731		15
279	Cannabis use during methadone maintenance treatment for opioid use disorder: a systematic review and meta-analysis. <b>2019</b> , 7, E665-E673		13

278	Sociodemographic Profiles and Clinical Outcomes for Clients on Methadone Maintenance Treatment in a Western Canadian Clinic: Implications for Practice. <b>2019</b> , 15, 231-241		3
277	Buprenorphine Use in Palliative Care. <b>2019</b> , 21, 540-547		3
276	Management of Opioid Use Disorder Treatment: An Overview. <b>2019</b> , 38, 118-126		2
275	Building a Group-Based Opioid Treatment (GBOT) blueprint: a qualitative study delineating GBOT implementation. <i>Addiction Science &amp; Clinical Practice</i> , <b>2019</b> , 14, 47	4.1	5
274	Treating patients with opioid use disorder. <b>2019</b> , 32, 10-11		2
273	Adjuvant laser meridian massage in men with opioid use disorder on methadone maintenance treatment: Protocol for a case-controlled study. <b>2019</b> , 98, e17319		2
272	Association between prenatal opioid exposure, neonatal opioid withdrawal syndrome, and neurodevelopmental and behavioral outcomes at 5-8 months of age. <b>2019</b> , 128, 69-76		21
271	Coprescribing of Benzodiazepines and Opioids in Older Adults: Rates, Correlates, and National Trends. <b>2019</b> , 74, 1910-1915		19
270	Generational trends and patterns in readmission within a statewide cohort of clients receiving heroin use disorder treatment in Maryland, 2007-2013. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 96, 82-91	4.2	1
269	Requiring Buprenorphine Waivers for Psychiatry Residents. <b>2019</b> , 43, 131-134		0
268	Delivering information about medication assisted treatment to individuals who misuse opioids through a mobile app: a pilot study. <b>2020</b> , 42, 149-154		4
267	How Should the United States Respond to the Opioid Addiction and Overdose Epidemic?. <b>2020</b> , 259-295		2
266	The effect of outpatient methadone maintenance treatment facilities on place-based crime. <b>2020</b> , 16, 227-245		2
265	Subcutaneous Buprenorphine for a Patient With a History of Misusing an Indwelling Catheter: A Case Report. <b>2020</b> , 61, 284-287		2
264	Cognitive-behavioral group therapy and buprenorphine: Balancing methodological rigor and community partner ethical concerns in efficacy-effectiveness trials. <b>2020</b> , 30, 364-384		
263	Initiating buprenorphine treatment for opioid use disorder during short-term in-patient 'detoxification': a randomized clinical trial. <i>Addiction</i> , <b>2020</b> , 115, 82-94	4.6	18
262	Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. <i>Journal of Substance Abuse Treatment</i> , <b>2020</b> , 108, 55-64	4.2	12
261	State targeted response to the opioid Crisis grants (opioid STR) program: Preliminary findings from two case studies and the national cross-site evaluation. <i>Journal of Substance Abuse Treatment</i> , <b>2020</b> , 108, 48-54	4.2	0



260	Managing Pain in the Setting of Opioid Use Disorder. <b>2020</b> , 21, 26-34		8
259	Opioid Craving in Human Laboratory Settings: a Review of the Challenges and Limitations. <b>2020</b> , 17, 100-104		4
258	Toward Addiction Prediction: An Overview of Cross-Validated Predictive Modeling Findings and Considerations for Future Neuroimaging Research. <b>2020</b> , 5, 748-758		12
257	Computational Markers of Risky Decision-making for Identification of Temporal Windows of Vulnerability to Opioid Use in a Real-world Clinical Setting. <b>2020</b> , 77, 368-377		13
256	Introduction to the special issue on innovative interventions and approaches to expand medication assisted treatment: Seizing research opportunities made available by the opioid STR program. <i>Journal of Substance Abuse Treatment</i> , <b>2020</b> , 108, 1-3	4.2	6
255	Treating Opioid Withdrawal With Buprenorphine in a Community Hospital Emergency Department: An Outreach Program. <b>2020</b> , 75, 49-56		14
254	Prince, politics, and doctors: A year in the news framing of a drug epidemic. <b>2020</b> , 1-12		
253	Patterns, contexts, and motivations for polysubstance use among people who inject drugs in non-urban settings in the U.S. Northeast. <i>International Journal of Drug Policy</i> , <b>2020</b> , 85, 102934	5.5	11
252	The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 216, 108244	4.9	4
251	Trends in Abstinence and Retention Associated with a Medication-Assisted Treatment Program for People with Opioid Use Disorders. <b>2020</b> , 14, 43-54		4
250	Reunification for young children of color with substance removals: An intersectional analysis of longitudinal national data. <b>2020</b> , 108, 104664		4
249	The opioid crisis: a contextual, social-ecological framework. <b>2020</b> , 18, 87		28
248	A systematic review of patients' and providers' perspectives of medications for treatment of opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , <b>2020</b> , 119, 108146	4.2	25
247	Imprecise action selection in substance use disorder: Evidence for active learning impairments when solving the explore-exploit dilemma. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 215, 108208	4.9	20
246	Point-of-Care Drug of Abuse Testing in the Opioid Epidemic. <b>2020</b> , 144, 1325-1334		1
245	Psycho-Social Correlates of Opioid Use Disorder among the US Adult Population: Evidence from the National Survey on Drug Use and Health, 2015-2018. <i>Substance Use and Misuse</i> , <b>2020</b> , 55, 2002-2010	2.2	8
244	Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use. <b>2020</b> , 47, 439-448		7
243	Review of Popularity and Quality Standards of Opioid-Related Smartphone Apps. <b>2020</b> , 7, 486-496		4

242	Catechins modulate the activity of mu opioid receptor (OR): An in silico approach. <b>2020</b> , 20, 100431		0
241	Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waived prescriber supply. <i>Journal of Substance Abuse Treatment</i> , <b>2020</b> , 115, 108032	4.2	10
240	Examining Recovery Program Participants by Gender: Program Completion, Relapse, and Multidimensional Status 12 Months After Program Entry. <i>Journal of Drug Issues</i> , <b>2020</b> , 50, 436-454	1.4	6
239	Experiences of Clients in Three Types of Methadone Maintenance Therapy in an Atlantic Canadian City: A Qualitative Study. <b>2021</b> , 53, 211-221		1
238	Determinism and Destigmatization: Mitigating Blame for Addiction. <b>2020</b> , 14, 219		2
237	Psychosocial Interventions in Office-Based Opioid Treatment: A Systematic Review. <b>2020</b> , 11, 103-131		4
236	Differences in patient-reported and observer-rated opioid withdrawal symptom etiology, time course, and relationship to clinical outcome. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 215, 108212	4.9	2
235	Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies. <b>2020</b> , 23, 1096-1108		2
234	Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study. <b>2020</b> , 35, 2529-2536		8
233	The Role of State Medicaid Expansions in Integrating Comprehensive Mental Health Services into Opioid Treatment Programs: Differences Across the Rural/Urban Continuum. <b>2021</b> , 57, 1017-1022		3
232	Some law enforcement officers' negative attitudes toward overdose victims are exacerbated following overdose education training. <b>2020</b> , 46, 577-588		8
231	Program development and implementation outcomes of a statewide addiction consultation service: Maryland Addiction Consultation Service (MACS). <b>2021</b> , 42, 595-602		0
230	Management of Opioid Misuse and Opioid Use Disorders Among Youth. <b>2020</b> , 145, S153-S164		6
229	Study protocol for a randomized controlled trial of mindfulness-based relapse prevention for opioid use disorders. <b>2020</b> , 99, 106182		2
228	Variation by race and ethnicity in the prevalence and trends of parental opioid misuse in child welfare: findings from the Regional Partnership Grant-1. <b>2020</b> , 1-20		0
227	Care for Incarcerated Pregnant People With Opioid Use Disorder: Equity and Justice Implications. <b>2020</b> , 136, 576-581		2
226	Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. <b>2020</b> , 15, 68		8
225	Sources of prescription opioids and tranquilizers for misuse among U.S. young adults: differences between high school dropouts and graduates and associations with adverse outcomes. <b>2021</b> , 39, 54-65		

224	Opioid Use Disorders in People Living with HIV/AIDS: A Review of Implications for Patient Outcomes, Drug Interactions, and Neurocognitive Disorders. <b>2020</b> , 8,		3
223	Efficacy of a Psychosocial Pain Management Intervention for Men and Women With Substance Use Disorders and Chronic Pain: A Randomized Clinical Trial. <b>2020</b> , 77, 1225-1234		5
222	Interest in reducing methamphetamine and opioid use among syringe services program participants in Washington State. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 216, 108243	4.9	5
221	The role of drug treatment and recovery services: an opportunity to address injection initiation assistance in Tijuana, Mexico. <b>2020</b> , 15, 78		0
220	Managing Acute Pain in Patients Taking Medication for Opioid Use Disorder: a Rapid Review. <b>2020</b> , 35, 945-953		3
219	The Cal-DSH diversion guidelines. <b>2020</b> , 25, 701-713		
218	The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US. <i>Drug and Alcohol Dependence</i> , <b>2020</b> , 212, 108067	4.9	7
217	Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016. <i>Journal of Substance Abuse Treatment</i> , <b>2020</b> , 114, 108028	4.2	13
216	Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , <b>2020</b> , 14, 99-112	3.8	25
215	Medication assisted treatment (MAT) in criminal justice settings as a double-edged sword: balancing novel addiction treatments and voluntary participation. <b>2020</b> , 8, 7		4
214	Full agonist opioid prescribing by primary care clinicians after buprenorphine training. <b>2020</b> , 1-7		5
213	Are Rural Opioid Treatment Program (OTP) Facilities Associated with Lower Deaths?. <i>Substance Use and Misuse</i> , <b>2020</b> , 55, 828-838	2.2	0
212	Preoperative Opioid Use Disorder Is Associated With Poorer Outcomes After Coronary Bypass and Valve Surgery: A Multistate Analysis, 2007-2014. <b>2020</b> , 34, 3267-3274		2
211	Substance use disorders: diagnosis and management for hospitalists. <b>2020</b> , 10, 117-126		3
210	Adherence to and Retention in Medications for Opioid Use Disorder Among Adolescents and Young Adults. <b>2020</b> , 42, 41-56		8
209	Reaching the 909090 UNAIDS treatment target for people who inject drugs receiving integrated clinical care at a drug-use outpatient treatment facility. <b>2020</b> , 1		
208	Nicotine and Opioids: a Call for Co-treatment as the Standard of Care. <b>2020</b> , 47, 601-613		4
207	Switching opioid-dependent patients in substitution treatment from racemic methadone, levomethadone and buprenorphine to slow-release oral morphine: Analysis of the switching process in routine care. <b>2020</b> , 144, 9-15		2

206	Aerobic Exercise Interventions for Patients in Opioid Maintenance Treatment: A Systematic Review.. <b>2020</b> , 14, 1178221820918885		2
205	Interaction effects in the association between methadone maintenance therapy and experiences of racial discrimination in U.S. healthcare settings. <b>2020</b> , 15, e0228755		10
204	Six-month retention and changes in quality of life and substance use from a low-threshold methadone maintenance therapy programme in Durban, South Africa. <i>Addiction Science &amp; Clinical Practice</i> , <b>2020</b> , 15, 13	4.1	6
203	Opioid agonist treatment and fatal overdose risk in a state-wide US population receiving opioid use disorder services. <i>Addiction</i> , <b>2020</b> , 115, 1683-1694	4.6	36
202	Pharmacotherapeutic management of co-morbid alcohol and opioid use. <b>2020</b> , 21, 823-839		7
201	Brief Training on Medication-Assisted Treatment Improves Community Mental Health Clinicians' Confidence and Readiness to Address Substance Use Disorders. <b>2020</b> , 56, 1429-1435		1
200	Treatment resistant opioid use disorder (TROUD): Definition, rationale, and recommendations. <b>2020</b> , 411, 116718		10
199	Adapting a peer recovery coach-delivered behavioral activation intervention for problematic substance use in a medically underserved community in Baltimore City. <b>2020</b> , 15, e0228084		14
198	Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. <b>2019</b> , 10, 955		34
197	Assessing factors associated with discharge from opioid agonist therapy due to incarceration in the United States. <b>2020</b> , 38, 1-18		3
196	A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use. <b>2020</b> , 15, 4		12
195	Prevalence and Health Characteristics of Prescription Opioid Use, Misuse, and Use Disorders Among U.S. Adolescents. <b>2020</b> , 66, 536-544		16
194	Correlates of death during outpatient treatment for opioid use disorder: A national study. <i>Journal of Substance Abuse Treatment</i> , <b>2020</b> , 112, 76-85	4.2	0
193	Racial/Ethnic and Gender Differences in Associations of Medication-Assisted Therapy and Reduced Opioid Use between Outpatient Treatment Admission and Discharge. <b>2020</b> , 52, 186-194		10
192	Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial. <b>2020</b> , 91, 105993		3
191	Applying principles of injury and infectious disease control to the opioid mortality epidemic in North America: critical intervention gaps. <b>2020</b> , 42, 848-852		2
190	Chronic Methadone Use Alters the CD8 T Cell Phenotype In Vivo and Modulates Its Responsiveness Ex Vivo to Opioid Receptor and TCR Stimuli. <b>2020</b> , 204, 1188-1200		4
189	Commentary on Krawczyk et al. (2020): Reinforcing the case for evidence-based treatment of opioid use disorder. <i>Addiction</i> , <b>2020</b> , 115, 1695-1696	4.6	

188	High retention in an opioid agonist therapy project in Durban, South Africa: the role of best practice and social cohesion. <i>Harm Reduction Journal</i> , <b>2020</b> , 17, 25	4.6	4
187	A dynamic model of the opioid drug epidemic with implications for policy. <b>2021</b> , 47, 5-15		4
186	Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 123, 108247	4.2	5
185	States Should Remove Barriers to Advanced Practice Registered Nurse Prescriptive Authority to Increase Access to Treatment for Opioid Use Disorder. <b>2021</b> , 22, 85-92		1
184	Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone. <i>Addiction</i> , <b>2020</b> , 116, 2084	4.6	3
183	A Critical Review of the Social and Behavioral Contributions to the Overdose Epidemic. <b>2021</b> , 42, 95-114		12
182	Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 122, 108222	4.2	3
181	Perspectives of people with opioid use disorder on improving addiction treatments and services. <i>Drugs: Education, Prevention and Policy</i> , <b>2021</b> , 28, 316-327	1.2	4
180	Pain Management in Former Addicts on Medication-Assisted Treatment (MAT) Program. <b>2021</b> , 309-325		0
179	Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone. <b>2021</b> , 11, 35-39		3
178	A Mobile Health App to Support Patients Receiving Medication-Assisted Treatment for Opioid Use Disorder: Development and Feasibility Study. <b>2021</b> , 5, e24561		3
177	'Resurgent', 'twin' or 'silent' epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America. <b>2021</b> , 16, 17		7
176	Medicaid Expansion and Availability of Opioid Medications in the Specialty Substance Use Disorder Treatment System. <b>2021</b> , 72, 148-155		2
175	Symptom severity and medication-assisted treatment for individuals with serious mental illness and a history of heroin use. <b>2021</b> , 296, 113671		
174	Understanding barriers to treatment among individuals not engaged in treatment who misuse opioids: A structural equation modeling approach. <b>2021</b> , 42, 842-850		1
173	Profiles and Predictors of Treatment-Resistant Opioid Use Disorder (TROUD): A Secondary Data Analysis of Treatment Episode Data Set-2017 Admissions. 1-16		
172	Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study). <b>2021</b> , 21, 100728		1
171	Trending the evidence on opioid use disorder (OUD) continuum of care among rural American Indian/Alaskan Native (AI/AN) tribes: A systematic scoping review. <b>2021</b> , 114, 106743		1

170	Facility Attractiveness and Social Vulnerability Impacts on Spatial Accessibility to Opioid Treatment Programs in South Carolina. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	3
169	Barriers and Challenges to Making Referrals for Treatment and Services for Opioid Misuse in Family Planning Settings. <b>2021</b> ,		
168	The Opioid Crisis: How Counselors Can and Should Respond. <b>2021</b> , 43, 112-124		0
167	Addiction is a Disability, and it Matters. 1		1
166	Implementation support for contingency management: preferences of opioid treatment program leaders and staff. <b>2021</b> , 2, 47		3
165	Imaging and Reimagining the Mind: fMRI and Psychiatric Illness. <b>2021</b> , 89, e45-e47		1
164	A mental health professional survey of cognitive-behavioral therapy for the treatment of opioid use disorder. <b>2021</b> , 77, 1607-1613		1
163	Using community engagement to implement evidence-based practices for opioid use disorder: A data-driven paradigm & systems science approach. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 222, 108675	4.9	5
162	Laser meridian massage decreased craving in men with opioid use disorder on methadone maintenance treatment. <b>2021</b> ,		0
161	Health Professional Stigma as a Barrier to Contingency Management Implementation in Opioid Treatment Programs. <b>2021</b> , 7, 166-176		2
160	Dance/Movement Therapists' Attitudes and Practices Toward Opioid Use Disorder. 1		
159	Sleep disturbance as a therapeutic target to improve opioid use disorder treatment. <b>2021</b> ,		4
158	Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 131, 108548	4.2	0
157	Medically treated opioid overdoses among New Jersey Medicaid beneficiaries: Rapid growth and complex comorbidity amid growing fentanyl penetration. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 131, 108546	4.2	3
156	Project ECHO and primary care buprenorphine treatment for opioid use disorder: Implementation and clinical outcomes. <b>2021</b> , 1-9		1
155	A systematic literature review of patient perspectives of barriers and facilitators to access, adherence, stigma, and persistence to treatment for substance use disorder.. <b>2021</b> , 2, 100029		2
154	Examining a migration-based phenomenon of heroin use in an urban drug scene in Sao Paulo, Brazil. <b>2021</b> , 17, 274-285		0
153	Buprenorphine Increases HIV-1 Infection In Vitro but Does Not Reactivate HIV-1 from Latency. <b>2021</b> , 13,		2

152	Jail and overdose: assessing the community impact of incarceration on overdose. <i>Addiction</i> , <b>2021</b> ,	4.6	5
151	Barriers for homeless with dual diagnosis: lessons learned from intensive mobile psychosocial assertive community treatment program. <b>2021</b> , ahead-of-print,		
150	Buprenorphine utilization among all Washington State residents' based upon prescription monitoring program data - Characteristics associated with two measures of retention and patterns of care over time. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 127, 108446	4.2	1
149	Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder. <b>2021</b> , 1		
148	Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 225, 108786	4.9	1
147	Substitution treatment for opioid dependence with slow-release oral morphine: Retention rate, health status, and substance use after switching to morphine. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 127, 108350	4.2	
146	Changes In Health Services Use After Receipt Of Medications For Opioid Use Disorder In A Statewide Correctional System. <b>2021</b> , 40, 1304-1311		0
145	Association between dynamic dose increases of buprenorphine for treatment of opioid use disorder and risk of relapse. <i>Addiction</i> , <b>2021</b> ,	4.6	0
144	Somewhere to Go: Implementing Medication-Based Treatment for Opioid Use Disorders in Rural Maryland and beyond.		0
143	A Narrative Literature Review of the Epidemiology, Etiology, and Treatment of Co-Occurring Panic Disorder and Opioid Use Disorder. <b>2021</b> , 17, 313-332		1
142	Racial/ethnic disparities in the use of medications for opioid use disorder (MOUD) and their effects on residential drug treatment outcomes in the US. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 226, 108849	4.9	7
141	Computational Mechanisms of Addiction: Recent Evidence and Its Relevance to Addiction Medicine. <b>2021</b> , 8, 509		1
140	Optimizing opioid use disorder treatment with naltrexone or buprenorphine. <i>Drug and Alcohol Dependence</i> , <b>2021</b> , 228, 109031	4.9	1
139	Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. <i>International Journal of Drug Policy</i> , <b>2021</b> , 98, 103380	5.5	3
138	Motherhood, substance use and peer support: Benefits of an integrated group program for pregnant and postpartum women. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 131, 108450	4.2	4
137	The impact of COVID-19 on opioid treatment program (OTP) services: Where do we go from here?. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 131, 108394	4.2	4
136	Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program. <i>Journal of Substance Abuse Treatment</i> , <b>2022</b> , 132, 108452	4.2	3
135	Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms. <i>Journal of Substance Abuse Treatment</i> , <b>2022</b> , 132, 108514	4.2	9

134	Barriers to treatment for opioid use disorder in Colombia. 1-7		2
133	Patient Satisfaction With Medications for Opioid Use Disorder Treatment via Telemedicine: Brief Literature Review and Development of a New Assessment. <b>2020</b> , 8, 557275		9
132	Stigma and Addiction Treatment. <b>2019</b> , 93-130		3
131	Spirituality/religion and substance use disorders. <b>2020</b> , 119-138		3
130	Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. <i>Journal of Substance Abuse Treatment</i> , <b>2019</b> , 100, 18-28	4.2	21
129	Substance Use Disorders: A Biopsychosocial Perspective. <b>2020</b> ,		2
128	Suicidal Ideation Among Heroin-Abusing Mothers in Methadone Maintenance Treatment. <b>2016</b> , 37, 461-464		1
127	Diverse diagnostic profiles associated with prescription opioid use disorder in a nationwide sample: One crisis, multiple needs. <b>2019</b> , 87, 849-858		12
126	The Law and Policy of Opioids for Pain Management, Addiction Treatment, and Overdose Reversal. <b>2017</b> , 14, 1		10
125	Hepatitis C virus (HCV) care in Canadian correctional facilities: Where are we and where do we need to be?. <b>2019</b> , 2, 171-183		7
124	Improving Access to Evidence-Based Medical Treatment for Opioid Use Disorder: Strategies to Address Key Barriers within the Treatment System.. <b>2020</b> , 2020,		34
123	Harm-Reduction Strategies for Injection Drug Use. <b>2017</b> , 47, 45-48		2
122	The Optimal Management of Opioid Use Disorder: Leveraging Advances in Addiction Psychopharmacology to Enhance Treatment Outcomes. <b>2018</b> , 48, 248-253		1
121	The Opioid Epidemic: What Does it Mean for Nurses?. <b>2017</b> , 55, 18-23		5
120	Nonmedical Prescription Opioid Use and DSM-5 Nonmedical Prescription Opioid Use Disorder in the United States. <b>2016</b> , 77, 772-80		161
119	Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 108647 <sup>4.2</sup>		0
118	Psychiatric Aspects of Cardiothoracic Surgery. <b>2019</b> , 109-130		
117	Totalavhold og skadereduksjon. <b>2019</b> , 3, 426-441		1



116 A Mobile Health App to Support Patients Receiving Medication-Assisted Treatment for Opioid Use Disorder: Development and Feasibility Study (Preprint).

115 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 380-435

114 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, xxiii-xxiv

113 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 67-92

112 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 539-592

111 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 213-254

110 Bridging Recovery Initiative Despite Gaps in Entry (BRIDGE): study protocol for a randomized controlled trial of a bridge clinic compared with usual care for patients with opioid use disorder. **2021**, 22, 757 0

109 Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study. **2021**, 1-12 1

108 Developing a Penal Abolitionist Application to Drug Treatment Drawing from Insider Perspectives and Lived Experiences. 016059762097878

107 Opioid agonist treatment uptake within provincial correctional facilities in British Columbia, Canada. *Addiction*, **2021**, 4.6 0

106 Treatment of substance use disorders among black and white adults: rates, correlates, and racial discrimination. **2021**, 1-12

105 Implementation of buprenorphine initiation and warm handoff protocols in emergency departments: A qualitative study of Pennsylvania hospitals. *Journal of Substance Abuse Treatment*, **2021**, 108658 4.2 2

104 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 3-31

103 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 32-66

102 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 95-119

101 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 120-162

100 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 165-212

99 Substance Use Disorders: A Biopsychosocial Perspective. **2020**, 255-302

98	Substance Use Disorders: A Biopsychosocial Perspective. <b>2020</b> , 305-338		
97	Substance Use Disorders: A Biopsychosocial Perspective. <b>2020</b> , 339-379		
96	Substance Use Disorders: A Biopsychosocial Perspective. <b>2020</b> , 436-483		
95	Substance Use Disorders: A Biopsychosocial Perspective. <b>2020</b> , 484-538		
94	Substance Use Disorders: A Biopsychosocial Perspective. <b>2020</b> , 593-620		
93	Substance Use Disorders: A Biopsychosocial Perspective. <b>2020</b> , 623-678		
92	Substance Use Disorders: A Biopsychosocial Perspective. <b>2020</b> , 679-791		
91	Self-reported Sleep Improvement in Buprenorphine MAT (Medication Assisted Treatment) Population. <b>2016</b> , 3,		9
90	Naltrexone: A History and Future Directions. <b>2018</b> , 2018,		3
89	Expanding the continuum of substance use disorder treatment: Nonabstinence approaches. <b>2021</b> , 91, 102110		2
88	Substance-Related and Addictive Disorders. <b>2022</b> , 235-287		
87	Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. <i>Addiction Science &amp; Clinical Practice</i> , <b>2021</b> , 16, 68	4.1	7
86	Treatment options and shared decision-making in the treatment of opioid use disorder: A scoping review. <i>Journal of Substance Abuse Treatment</i> , <b>2021</b> , 108646	4.2	
85	A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder. <i>Addiction Science &amp; Clinical Practice</i> , <b>2021</b> , 16, 70	4.1	1
84	Perceptions of E-cigarettes among adults in treatment for opioid use disorder. <b>2022</b> , 2, 100023		
83	Buprenorphine/Naloxone for Opioid Use Disorder Among Alaska Native and American Indian People. <i>Journal of Addiction Medicine</i> , <b>2021</b> , 15, 297-302	3.8	0
82	Opioid-specific medication-assisted therapy and its impact on criminal justice and overdose outcomes. <i>Campbell Systematic Reviews</i> , <b>2022</b> , 18,	2.1	1
81	Real-world effectiveness of pharmacological treatments of opioid use disorder in a national cohort.. <i>Addiction</i> , <b>2022</b> ,	4.6	0

80	State-level regulations and opioid-related health outcomes.. <i>Drug and Alcohol Dependence</i> , <b>2022</b> , 232, 109294	4.9	
79	Opioid Analgesics, Tolerance, Dependence and Addiction. <b>2022</b> , 367-374		
78	La pratique émergente de la pharmacothérapie de remplacement. <i>Drogues, Santé Et Société</i> , <b>2021</b> , 19, 258	0.1	
77	Addiction Psychiatry. <b>2022</b> , 201-206		
76	Acceptance of medications for opioid use disorder in recovery housing programs in Missouri.. <i>Journal of Substance Abuse Treatment</i> , <b>2022</b> , 108747	4.2	1
75	High cardiovascular risk in older patients with opioid use disorder: Differences with the general population.. <i>Drug and Alcohol Review</i> , <b>2022</b> ,	3.2	
74	Implementing injectable opioid agonist treatment: a survey of professionals in the field of opioid use disorders. <i>Drugs: Education, Prevention and Policy</i> , 1-9	1.2	
73	Review of medication-assisted treatment for opioid use disorder.. <i>Journal of Osteopathic Medicine</i> , <b>2022</b> ,	0.8	0
72	The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder.. <i>Journal of Substance Abuse Treatment</i> , <b>2022</b> , 108775	4.2	0
71	Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health.. <i>Journal of Substance Abuse Treatment</i> , <b>2022</b> , 108776	4.2	1
70	Modeling the Dynamics of Heroin and Illicit Opioid Use Disorder, Treatment, and Recovery.. <i>Bulletin of Mathematical Biology</i> , <b>2022</b> , 84, 48	2.1	0
69	Simple, Rapid Spectrophotometric Assay of Dispensed Methadone for Diversion Control.. <i>Journal of Addiction Medicine</i> , <b>2022</b> ,	3.8	
68	Comparing Perceptions of Addiction Treatment between Professionals and Individuals in Recovery.. <i>Substance Use and Misuse</i> , <b>2022</b> , 57, 983-994	2.2	
67	Interest in electronic cigarettes for smoking cessation among adults with OUD in buprenorphine treatment: A mixed-methods investigation.. <i>Nicotine and Tobacco Research</i> , <b>2021</b> ,	4.9	0
66	Addiction Treatment as Prison Governance: A Critical Discourse Analysis of Methadone Delivery in Kyrgyz Prisons. <i>Contemporary Drug Problems</i> , <b>2022</b> , 49, 106-120	1.3	1
65	Using Mindfulness-Based Cognitive Therapy to Prevent Suicide Among High Suicide Risk Patients Who Also Misuse Opioids: a Preliminary Probe of Feasibility and Effectiveness. <i>International Journal of Mental Health and Addiction</i> , 1	8.8	
64	State Policies and Buprenorphine Prescribing by Nurse Practitioners and Physician Assistants.. <i>Medical Care Research and Review</i> , <b>2022</b> , 10775587221086489	3.7	1
63	"Just give them a choice": Patients' perspectives on starting medications for opioid use disorder in the ED.. <i>Academic Emergency Medicine</i> , <b>2022</b> ,	3.4	0

62 DataSheet\_1.pdf. **2020**,

61 Folate Status as a Nutritional Indicator among People with Substance Use Disorder; A Prospective Cohort Study in Norway.. *International Journal of Environmental Research and Public Health*, **2022**, 19, 4.6 1

60 Factors associated with 60-day adherence to "safer supply" opioids prescribed under British Columbia's interim clinical guidance for health care providers to support people who use drugs during COVID-19 and the ongoing overdose emergency.. *International Journal of Drug Policy*, **2022**, 105, 103709 5.5 2

59 Treatment Outcomes Associated with Medications for Opioid Use Disorder (MOUD) Among Criminal Justice-Referred Admissions to Residential Treatment in the U.S.,2015-2018. *Drug and Alcohol Dependence*, **2022**, 109498 4.9

58 Use of Long-Acting Injectable Buprenorphine in the Correctional Setting. *SSRN Electronic Journal*, 1

57 Treatment Experiences Among People Who Use Opioids: A Social Ecological Approach. *Qualitative Health Research*, 104973232211043 3.9 1

56 Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic. *Harm Reduction Journal*, **2022**, 19, 4.6 0

55 The X Waiver to Prescribe Buprenorphine: The Why and How. *Journal of Palliative Medicine*, **2022**, 25, 1021-1023 2.2 0

54 Patient-Centered Outcomes associated with a Novel Office-Based Opioid Treatment Program in a District Health Department: A Mixed-Method Pilot Study (Preprint).

53 Program, Policy and Social Support Characteristics Associated With Rural vs. Urban Recovery Housing, 2018-2020. *Journal of Drug Issues*, 002204262211140 1.4

52 Pharmacotherapy of Opioid Use Disorder Update and Current Challenges. **2022**,

51 Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province. **2022**, 22,

50 The measurement-based care to opioid treatment programs project (MBC2OTP): a study protocol using rapid assessment procedure informed clinical ethnography. **2022**, 17, 0

49 Managing Opioid Withdrawal in an Outpatient Setting With Lofexidine or Clonidine. **2022**,

48 Barriers and Facilitators to DATA Waivered Providers Prescribing Buprenorphine: A Qualitative Analysis Applying the Theory of Planned Behavior. 1-11

47 Anterior cingulate cortex and its projections to the ventral tegmental area regulate opioid withdrawal, the formation of opioid context associations and context-induced drug seeking. 16,

46 Under-representation of key demographic groups in opioid use disorder trials. **2022**, 4, 100084

45 The association between medication for opioid use disorder and employment outcomes in the U.S.: The relevance of race and ethnicity. **2022**, 4, 100081

44	Education as drug policy: A realist synthesis of continuing professional development for opioid agonist therapy. <b>2022</b> , 108, 103807	
43	Use of long-acting injectable buprenorphine in the correctional setting. <b>2022</b> , 142, 108851	1
42	¶m putting a Band-Aid on a bullet hole the only way I know how:¶Barriers and facilitators of opioid use and recovery in Nevada.	0
41	The Lived Experience of Medication for Opioid Use Disorder. Publish Ahead of Print,	0
40	Reducing opioid use disorder health inequities within Latino communities in South Texas.	0
39	Buprenorphine/naloxone versus methadone opioid rotation in patients with prescription opioid use disorder and chronic pain: study protocol for a randomized controlled trial. <b>2022</b> , 17,	0
38	Association between Prescribers¶Perceptions of the Utilization of Medication for Opioid Use Disorder and Opioid Dependence Treatability. <b>2022</b> , 10, 1733	0
37	Association Between Buprenorphine Treatment Gaps, Opioid Overdose, and Health Care Spending in US Medicare Beneficiaries With Opioid Use Disorder.	0
36	Prevention, diagnosis, and treatment of opioid use disorder under the supervision of opioid stewardship programs: it¶ time to act now. <b>2022</b> , 35, 361-382	3
35	Hot off the Press: Medications For Opioid Use Disorder In The Emergency Department.	0
34	Substance Use Disorders: Second Wave Approaches. <b>2022</b> , 563-582	0
33	Research Participation in Substance Use Disorder Trials: Design and Methods of a Multi-Site Nested Qualitative Study. <b>2022</b> , 21, 160940692211311	0
32	Current and emerging pharmacotherapies for opioid dependence treatments in adults: a comprehensive update.	0
31	Workplace Supported Recovery from Substance Use Disorders: Defining the Construct, Developing a Model, and Proposing an Agenda for Future Research.	0
30	Do Policies to Increase Access to Treatment for Opioid Use Disorder Work?.	0
29	Digital interventions for opioid use disorder treatment: A systematic review of randomized controlled trials. <b>2022</b> , 108926	0
28	Suboxone: History, controversy, and open questions. 13,	0
27	The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study. <b>2022</b> , 109678	0

- 26 Total cost of care associated with opioid use disorder treatment. **2022**, 107345 ○
- 25 I'm putting a Band-Aid on a bullet hole the only way I know how: A qualitative study of barriers and facilitators to opioid misuse and recovery in Nevada. **2022**, 17, ○
- 24 Promoting permanency in families with parental substance misuse: lessons from a process evaluation of a multi-system program. **2022**, 22, ○
- 23 Using machine learning to study the effect of medication adherence in Opioid Use Disorder. **2022**, 17, e0278988 ○
- 22 Demographic and Socioeconomic Correlates to Buprenorphine Access in Pharmacies. **2022**, ○
- 21 The Effect of 3 Years of Methadone Maintenance Therapy on Biochemical and Biophysical Parameters of Opioid Use Disorder Patients. ○
- 20 The Role of Social Science in Substance Use Disorders and Addiction. **2023**, 1-21 ○
- 19 Telemedicine Use and Quality of Opioid Use Disorder Treatment in the US During the COVID-19 Pandemic. **2023**, 6, e2252381 ○
- 18 Patient-Centered Outcomes associated with a Novel Office-Based Opioid Treatment Program in a District Health Department: A Mixed-Method Pilot Study (Preprint). ○
- 17 General therapy strategies in opioid addiction. **2023**, 289-307 ○
- 16 Editorial. **2023**, 16, 1-2 ○
- 15 Transcriptional and epigenetic regulation of microglia in substance use disorders. **2023**, 125, 103838 ○
- 14 Natural Polyphenols Resveratrol, Quercetin, Magnolol, and Epicatechin Block Certain Aspects of Heroin Addiction and Modulate Striatal IL-6 and TNF- $\alpha$ . **2023**, 11, 379 ○
- 13 A scoping review of the opioid epidemic among U.S. Immigrants: Implications for treatment practices. 1-19 ○
- 12 Oral buprenorphine utilization, concomitant benzodiazepines and opioid analgesics, and payment source: Trends from 2015 to 2019. **2023**, 147, 208980 ○
- 11 The impact of the COVID-19 pandemic on medications for opioid use disorder services in the U.S. and Canada: a scoping review. 1-14 ○
- 10 The Role of Physical Exercise in Opioid Substitution Therapy: Mechanisms of Sequential Effects. **2023**, 24, 4763 ○
- 9 A legal dispute resolution intervention for patients with substance use disorders: a study protocol for a randomized controlled trial. **2023**, 23, ○

- 8 Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey. **2023**, 20, ○
- 7 People with opioid use disorders: A taxonomy of treatment entrants to support the development of a profile-based approach to care. ○
- 6 Measurement Approaches to Estimating Methadone Continuity in Opioid Use Disorder Care. **2023**, 61, 314-320 ○
- 5 [A Profound, Abiding Hatred—An Analysis of Hermann Goering’s Alleged Morphine Addiction.](#) **2023**, ○
- 4 Differences in Behavioral Health Clinician Comfort Discussing Medication to Treat Substance Use Disorders. 1-2 ○
- 3 Interest in treatment with injectable diacetylmorphine among people who use opioids in Baltimore City, Maryland (USA). **2023**, 55, ○
- 2 Barriers to opioid use disorder treatment: A comparison of self-reported information from social media with barriers found in literature. 11, ○
- 1 Implications of neuroimaging findings in addiction. **2023**, 3, ○